← FDA DRUG APPROVALS

FDA ANDA · ANDA203955

ROPIVACAINE HYDROCHLORIDE

Sponsor: RISING

APPLICATION
ANDA203955
TYPE
ANDA
ORIGINAL APPROVAL
2016-04-11
LATEST ACTION
2025-08-06
ROUTE
INJECTION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ROPIVACAINE HYDROCHLORIDEPrescription
ROPIVACAINE HYDROCHLORIDE 150MG/30ML (5MG/ML) · SOLUTION · INJECTION

Approval history

2025-08-06Labeling · Supplement 2 · standardAP
2025-08-06Labeling · Supplement 8 · standardAP
2016-04-11UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →